Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Notes Payables (2016 - 2023)

Historic Notes Payables for Ocular Therapeutix (OCUL) over the last 9 years, with Q2 2023 value amounting to $2.1 million.

  • Ocular Therapeutix's Notes Payables changed N/A to $2.1 million in Q2 2023 from the same period last year, while for Jun 2023 it was $2.1 million, marking a year-over-year change of. This contributed to the annual value of $8.3 million for FY2020, which is N/A changed from last year.
  • Per Ocular Therapeutix's latest filing, its Notes Payables stood at $2.1 million for Q2 2023.
  • Over the past 5 years, Ocular Therapeutix's Notes Payables peaked at $8.3 million during Q4 2020, and registered a low of $2.1 million during Q1 2020.
  • Moreover, its 3-year median value for Notes Payables was $5.2 million (2020), whereas its average is $5.2 million.
  • The largest annual percentage gain for Ocular Therapeutix's Notes Payables in the last 5 years was 29971.07% (2021), contrasted with its biggest fall of 29971.07% (2021).
  • Over the past 3 years, Ocular Therapeutix's Notes Payables (Quarter) stood at $8.3 million in 2020, then changed by 0.0% to $8.3 million in 2021, then tumbled by 74.87% to $2.1 million in 2023.
  • Its last three reported values are $2.1 million in Q2 2023, $8.3 million for Q1 2021, and $8.3 million during Q4 2020.